

Freedom of Information Request	FOI 23-362	31 st July 2023
--------------------------------	------------	----------------------------

In the past 3 months [latest 3 months available] how many patients have received the following treatments [for any disease]:

Berinert (Human C1-esterase inhibitor)

Cinryze (Human C1-esterase inhibitor)

Orladeyo (berotralstat)

Takhzyro (Lanadelumab)

Ruconest (Recombinant human C1-esterase inhibitor)

Firazyr (Icatibant)

Icatibant – any brand except Firazyr

The Health Board is unable to provide information on the number of patients treated with specific drugs. However, please find below the quantities dispensed across Health Board pharmacies for any medical condition, for the period April 2023 – June 2023:

Biologic Drug	Quantity
ICATIBANT 30 mg in 3mL Pre-Filled Syringe 1 Pre-Filled Syringe Pack	2